Core Insights - Edgewell Personal Care (EPC) reported revenue of $537.2 million for the quarter ended September 2025, marking a year-over-year increase of 3.8% [1] - The earnings per share (EPS) for the same period was $0.68, down from $0.72 a year ago, indicating a decline [1] - The reported revenue exceeded the Zacks Consensus Estimate of $536.03 million by 0.22%, while the EPS fell short of the consensus estimate of $0.82 by 17.07% [1] Revenue Performance - Net Sales in Feminine Care reached $67.3 million, slightly below the average estimate of $67.62 million, reflecting a year-over-year increase of 0.9% [4] - Net Sales in Wet Shave amounted to $321.9 million, compared to the estimated $328.88 million, showing a year-over-year increase of 1.2% [4] - Net Sales in Sun and Skin Care were reported at $148 million, surpassing the average estimate of $139.53 million, with a significant year-over-year increase of 11.5% [4] Stock Performance - Over the past month, shares of Edgewell Personal have declined by 6.2%, contrasting with the Zacks S&P 500 composite's increase of 4.6% [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3]

Financial Data and Key Metrics Changes - In Q4, the company generated organic net sales growth of 2.5%, aligning with expectations in international markets and showing progress in North America [7][22] - Adjusted gross margin rate decreased by 330 basis points, primarily due to higher-than-anticipated inventory adjustments and increased trade promotions [27][28] - Adjusted operating income was $40.3 million, or 7.5% of net sales, compared to $56 million, or 10.8% of net sales last year [28] Business Line Data and Key Metrics Changes - International organic net sales grew by 6.9%, driven by volume and price gains across all segments [22] - North America experienced a decline in organic net sales of approximately 1%, with Wet Shave declining by about 1% while Sun Care and Grooming showed growth [23][24] - Grooming organic net sales grew by 9%, led by over 28% growth in Cremo [26] Market Data and Key Metrics Changes - International markets represented approximately 40% of global sales and delivered strong growth for the fourth consecutive year [8] - Europe generated its third straight year of growth, and Greater China delivered double-digit growth [9] - In the U.S. razor and blades category, consumption was down 80 basis points in the quarter, although market share improved sequentially [23] Company Strategy and Development Direction - The company plans to divest its Feminine Care business to focus on core categories with competitive advantages, including Shave, Sun, and Skin Care [6][19] - A multi-year innovation roadmap is being implemented, with significant investments in brand building and marketing [11][12] - The company aims to optimize its North American Wet Shave business and manufacturing footprint to enhance productivity and efficiency [10][12] Management Comments on Operating Environment and Future Outlook - Management acknowledged significant external pressures, including tariffs and foreign exchange volatility, impacting financial performance [8][20] - The outlook for fiscal 2026 anticipates a return to organic net sales growth, driven by mid-single-digit growth in international markets and stabilization in North America [16][33] - The company expects to face challenges from inflation and tariffs but is focused on productivity gains and brand investments to support growth [16][35] Other Important Information - The company declared a $0.15 per share dividend for Q4 and returned approximately $7 million to shareholders via dividends [29] - The anticipated divestiture of the Feminine Care business is expected to impact adjusted EPS by approximately $0.40-$0.50 annually [32] Q&A Session Summary Question: Outlook and EPS in Q1 - Management indicated that the 2026 plan is balanced and achievable, with expectations for low single-digit category growth and maintaining market share [42][43] Question: Strategy and M&A Intentions - The focus is on winning in Shave, Grooming, Sun, and Skin categories, with potential for M&A as asset values decline [51][54] Question: Productivity and Gross Margin Concerns - Management expressed confidence in the second-half-oriented plan, expecting higher sales growth and productivity improvements to enhance gross margin [64][66] Question: Sun and Skin Category Outlook - The company plans conservatively for the Sun season, with clean inventory levels and new campaigns for Hawaiian Tropic and Banana Boat [82]

Financial Data and Key Metrics Changes - In Q4, the company achieved organic net sales growth of 2.5%, aligning with expectations despite external pressures [7][22] - Adjusted gross margin rate decreased by 330 basis points, primarily due to unexpected year-end inventory adjustments and increased trade promotions [27][28] - Adjusted operating income was $40.3 million, representing 7.5% of net sales, down from 10.8% in the previous year [28] Business Line Data and Key Metrics Changes - International organic net sales grew by 6.9%, driven by volume and price gains across all segments [22] - North America experienced a decline in organic net sales by 60 basis points, with wet shave sales down approximately 1% [23] - Sun and skin care organic net sales increased by approximately 11%, with robust growth across each business segment [24] Market Data and Key Metrics Changes - International markets, representing about 40% of global sales, delivered strong growth for the fourth consecutive year, with Europe achieving its third straight year of growth [8][9] - The U.S. razor and blades category saw consumption down by 80 basis points, although market share improved sequentially [23] - The Billie brand achieved a 90 basis point share growth, now holding a 15% share at Walmart and 13% at Target [24] Company Strategy and Development Direction - The company plans to divest its feminine care business to focus on core categories with competitive advantages, including shave, sun, and skincare [6][19] - A multi-year innovation roadmap is being implemented, with significant investments in brand building and marketing to restore brand equity [11][14] - The transformation plan aims to simplify the U.S. structure, enabling faster decision-making and increased investment in growth capabilities [12][15] Management's Comments on Operating Environment and Future Outlook - The management acknowledged a challenging fiscal 2025 due to external pressures like tariffs and geopolitical tensions, but expressed confidence in the foundation for future growth [8][19] - For fiscal 2026, the company anticipates a return to organic net sales growth, driven by mid-single-digit growth in international markets and stabilization in North America [16][33] - The macro environment is expected to remain challenging, with muted category growth and cautious consumer spending [15][16] Other Important Information - The company generated productivity savings of 270 basis points in fiscal 2025, with expectations of approximately 310 basis points in fiscal 2026 [10][30] - Adjusted EBITDA for fiscal 2026 is projected to be in the range of $290 million to $310 million, approximately flat to the prior year [37] - The divestiture of the feminine care business is expected to impact adjusted EPS by approximately $0.40 to $0.50 annually [32] Q&A Session Summary Question: Outlook and EPS Expectations - The company expects a balanced and achievable plan for 2026, with low single-digit category growth assumptions and flexibility to maintain profit goals [41][43] Question: Strategy and M&A Intentions - The focus is on winning in shave, grooming, sun, and skin categories, with potential for M&A as asset values decline [51][53] Question: Productivity and Gross Margin Concerns - The company is confident in its second-half-oriented plan, expecting higher sales growth and productivity improvements to offset margin pressures [63][64] Question: Sun and Skin Category Insights - The company plans conservatively for the sun season, expecting low single-digit growth while focusing on brand campaigns and distribution gains [81][84]

Core Insights - Edgewell Personal Care Company reported a 3.8% increase in fourth quarter net sales, reaching $537.2 million, with a 2.5% organic growth [5][12] - For fiscal year 2025, net sales decreased by 1.3% to $2,223.5 million, with organic sales also declining by 1.3% [12][16] - The company returned $120 million to shareholders through dividends and share repurchases during fiscal year 2025 [12][23] Financial Performance - Gross profit for the fourth quarter was $208.6 million, down from $212.8 million in the prior year, resulting in a gross margin of 38.8%, a decrease of 230 basis points [6][12] - Adjusted operating income for the fourth quarter was $40.3 million, or 7.5% of net sales, compared to $56.0 million, or 10.8% in the prior year [9][12] - The company recorded a net loss of $30.6 million for the fourth quarter, translating to a loss of $0.66 per diluted share, compared to a profit of $8.8 million or $0.17 per diluted share in the prior year [12][22] Segment Performance - Wet Shave segment net sales increased by 1.2% to $318.2 million, while organic net sales decreased by 0.8% due to volume declines in North America [13][38] - Sun and Skin Care segment net sales rose by 11.5% to $148.0 million, with organic growth of 11.1% driven by volume growth [14][38] - Feminine Care segment net sales increased slightly by 0.9% to $67.3 million, but segment profit decreased by 22.6% [15][38] Strategic Initiatives - The company announced the divestiture of its Feminine Care business to Essity for $340 million, marking a significant strategic shift [12][13] - Edgewell aims to return to organic sales growth in 2026, with a focus on execution, margin recovery, and sustainable shareholder value [4][12] - The company plans to incur pre-tax charges of approximately $49 million in fiscal 2026 for restructuring and efficiency improvements [25][24]

Core Insights - Essity has announced the acquisition of Edgewell Feminine Care business in North America, indicating a strategic move to enhance its market position in the feminine care segment [1][2] Group 1: Acquisition Details - The acquisition aims to strengthen Essity's portfolio in the feminine care market, which is expected to provide synergies and growth opportunities [1] - The announcement was made during an audiocast led by Essity's Head of Investor Relations, Sandra Åberg, highlighting the significance of the acquisition [1] Group 2: Leadership Presentation - The presentation included insights from Essity's President and CEO, Ulrika Kolsrud, and CFO, Fredrik Rystedt, who discussed the financial implications and strategic rationale behind the acquisition [2] - Presentation materials were made available on Essity's website, ensuring transparency and accessibility for stakeholders [2]

Core Insights - Edgewell Personal Care has agreed to sell its North American feminine care business to Essity for $340 million [1] Group 1: Transaction Details - The sale includes products such as Stayfree sanitary napkins [1] - The transaction is valued at $340 million [1] Group 2: Strategic Implications - The acquisition by Essity reflects its strategy to expand in the health and hygiene sector [1]

Core Insights - Essity has agreed to acquire Edgewell Personal Care's feminine care business for USD 340 million, enhancing its position in the North American hygiene market [1][3] - The acquisition includes well-known brands such as Carefree, Stayfree, and o.b., as well as global rights for Playtex and a production facility in Dover, Delaware [1][3] - The deal is expected to close in the first quarter of 2026, pending regulatory approvals [1] Financial Summary - The purchase price of USD 340 million represents an EBITDA multiple of approximately 12.1x based on pro-forma IFRS as of June 30, 2025, and 8.3x when including estimated run-rate synergies [1] - For the 12 months ending June 30, 2025, the acquired business reported net sales of USD 261 million and a segment operating profit of USD 17 million [1] Strategic Implications - This acquisition aligns with Essity's strategy to focus on high-margin categories and strengthen its market position in the US, the largest hygiene market globally [1] - Essity aims to leverage its established success in the feminine care sector to grow the acquired brands [1]

Core Viewpoint - Edgewell Personal Care Company has entered into a definitive agreement to sell its feminine care business to Essity for $340 million, aiming to streamline its portfolio and focus on core competitive areas [1][2][3]. Transaction Details - The transaction is expected to close in the first quarter of calendar 2026, pending regulatory approvals [2]. - Edgewell's feminine care brands include Playtex®, Stayfree®, Carefree®, and o.b.® [2]. - Proceeds from the sale will primarily be used to strengthen Edgewell's balance sheet and invest in long-term growth of its core businesses [2]. Strategic Implications - The sale is seen as a pivotal step in Edgewell's transformation, allowing the company to sharpen its focus on core categories and enhance its financial position for sustainable growth [3]. - The acquisition will enable Essity to strengthen its personal care business in North America, aligning with its strategy to focus on high-yield categories [3]. Transition Support - Edgewell will collaborate with Essity to ensure a smooth transition for employees, customers, and consumers, providing certain services to support the transition post-transaction [4]. Financial Impact - Beginning in the first quarter of fiscal 2026, Edgewell will classify the feminine care business as discontinued operations [5]. - The sale is expected to impact adjusted EPS by approximately $0.40 to $0.50 and adjusted EBITDA by $35 to $45 million, net of income from transition support services [5].

Core Insights - Edgewell Personal Care (EPC) is set to release its fourth-quarter 2025 earnings on November 13, with an anticipated earnings per share (EPS) of $0.82 and projected revenue of $532.82 million, which could influence stock movement [1] Financial Performance - The expected EPS of $0.82 indicates a 13.9% increase from the same period last year, reflecting the company's growth trajectory [2] - The projected revenue of $532.82 million represents a 3.6% rise from the previous year's quarter, despite a prior revenue decline of 3.2% reported on August 5 [3] - The previous earnings report showed earnings of $0.92 per share, missing analysts' expectations of $1.01, with revenue falling short of the forecasted $658.51 million [3] Market Valuation - EPC has a price-to-earnings (P/E) ratio of approximately 13.70, indicating moderate market valuation of its earnings [4] - The price-to-sales ratio of 0.39 and enterprise value to sales ratio of 0.94 suggest a relatively low market valuation compared to its revenue [4] - The company's debt-to-equity ratio of 0.90 reflects a balanced approach to leveraging debt versus equity [4] Financial Stability - EPC's current ratio of 1.77 demonstrates its ability to cover short-term liabilities with short-term assets, indicating a stable financial footing [5]

Core Insights - Kenvue Inc. (NYSE:KVUE) experienced a significant increase in share prices, rising by 17.47% week-on-week, driven by strong earnings and a merger announcement with Kimberly-Clark valued at $48.7 billion [1][3]. Financial Performance - Kenvue reported a net income of $398 million for the third quarter, reflecting a 4% increase from $383 million in the same period last year [3]. - Net sales decreased by 3.46%, falling to $3.764 billion from $3.899 billion year-on-year [3]. Merger Details - Kenvue has agreed to merge with Kimberly-Clark, with the acquisition terms set at $3.50 in cash and 0.14625 of Kimberly-Clark shares per KVUE share, totaling $21.01 based on Kimberly-Clark's closing price as of October 31, 2025 [2]. - The merger is expected to consolidate several well-known brands, including Tylenol, Aveeno, Huggies, Kotex, Listerine, Neutrogena, and Band-Aid under one entity [2]. Future Outlook - For the full year 2025, Kenvue anticipates a low single-digit decline in both net sales and organic sales, with adjusted diluted earnings per share projected between $1.00 and $1.05 [4].